Unpartnered Products: 2015 Updates

The pharmaceutical industry is ripe for the picking with a virtual smorgasbord of unpartnered product opportunities in our 2015 update. As smaller biotech and pharma companies continue to advance their pipelines to meet unmet needs they are faced with the burning question of where to allocate their limited financial resources. Should these companies continue to spend money to further develop their pipeline candidates to market or should they out-license drugs further along in development and go back to the drawing board to identify new products?

Unpartnered Products: 2015 Update

The following analysis re-examines: unpartnered branded, investigational & biologic drugs, private company pipelines with unpartnered products, public company pipelines with less than one year of cash on hand, recent licensing deals and royalties.